Modified Dialectical Behavior Therapy for Treating Anxiety and Depression
Adaptation of Individual Dialectical Behavior Therapy Intervention for Transdiagnostic Treatment of Emotional Disorders in Two Medical Centers: a Randomized Controlled Trial
This study is testing a new type of therapy called modified Dialectical Behavior Therapy to see if it can help people with anxiety and depression feel better and improve their quality of life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 250 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Mackay Memorial Hospital Academic / other |
| Locations | 1 site (Taipei) |
| Trial ID | NCT05989451 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the efficacy of a modified Dialectical Behavior Therapy (DBT) intervention for the transdiagnostic treatment of anxiety and depressive disorders. Conducted over three years, the study will involve a randomized controlled design with two parallel groups at two medical centers in Taiwan. Participants will receive 12 weekly individual therapy sessions, and their clinical outcomes will be assessed before, after, and three months post-intervention. The goal is to determine whether this modified DBT approach can improve the severity of emotional disorders and enhance overall quality of life.
Who should consider this trial
Good fit: Ideal candidates for this study are Mandarin-speaking individuals currently diagnosed with anxiety or depressive disorders.
Not a fit: Patients with intellectual disabilities, substance use disorders, or severe mental health conditions such as bipolar or psychotic disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve treatment outcomes for patients suffering from anxiety and depressive disorders.
How similar studies have performed: Preliminary studies on transdiagnostic psychotherapy approaches, including DBT, have shown encouraging results, suggesting potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Mandarin Chinese-language proficiency sufficient to complete study questionnaire 2. A current diagnosis of depressive or anxiety disorder as diagnosed from a SCAN interview Exclusion Criteria: 1. Intellectual disability 2. Substance use disorder in the past three months 3. Bipolar disorder 4. Psychotic disorder 5. Organic brain disorder 6. Acute suicidality or a history of frequent or recent suicide attempts 7. Recent (past six weeks) change in psychiatric medication or unwillingness to maintain a stable dosage of medication during study participation 8. Had received five or more sessions of CBT in the past five years or unwilling to stop concurrent psychotherapy for an emotional disorder 9. Any mental or physical condition requiring hospital admission 10. Another medical condition likely to prevent participation in the study
Where this trial is running
Taipei
- MacKay Memorial Hospital — Taipei, Taiwan (Recruiting)
Study contacts
- Principal investigator: Shen-Ing Liu, Ph.D — Mackay Memorial Hospital
- Study coordinator: Hui-Chun Huang, Ph.D
- Email: aihch@mmh.org.tw
- Phone: 886-2-28094661
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.